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Current understanding of IGF-I-mediated neuroprotection implies the activation of phosphatidylinositol-3-kinase (PI-3K), which leads to
the activation of Akt/Protein Kinase B. In non-neuronal cells, Akt phosphorylates and activates the transcription factor CREB, implicated in
the transcription of the anti-apoptotic bcl-2 gene. This paper further analyses the anti-apoptotic IGF-I action in neurons. We show that IGF-I
protects cortical neurons against ceramide-induced apoptosis. Ceramide decreases Akt phosphorylation during apoptotic process whereas a
simultaneous treatment with IGF-I increases Akt phosphorylation. Analysis of the signal transduction pathways revealed that IGF-I induces
CREB phosphorylation via PI-3K and ERK, whereas simultaneous ceramide and IGF-I treatment decreases CREB phosphorylation.
Although an overexpression of Bcl-2 protects cortical neurons against ceramide-induced apoptosis, our data indicate that the Bcl-2 protein
level is not modulated during IGF-I, ceramide and/or LY294002 treatment. In consequence, we demonstrated that IGF protects neurons
against ceramide-induced apoptosis and that IGF-I protection involves the PI-3K/Akt and ERK pathways; this protection may be independent
of CREB and Bcl-2.
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Insulin-like Growth Factor-I (IGF-I) belongs to the
somatomedin group of polypeptide hormones [12]. IGF-I
has neuroprotective properties by reducing programmed
death of motorneurons during development, after axotomy
and spinal cord transection [34,35,42]. Intraventricular
application of IGF-I has shown to attenuate neuronal cell
loss after hypoxic–ischemic brain injury in adult rats
[22,56,57]. In vitro studies revealed that IGF-I exerts its
biological actions through a tyrosine kinase receptor,
responsible for the phosphorylation of intracellular signal
transduction proteins [59]. IGF-I-mediated neuroprotection
is induced through the activation of the phosphatidylinosi-
tol-3-kinase (PI-3K), as demonstrated for cerebellar granule142 (2005) 97 – 106
S. Willaime-Morawek et al. / Molecular Brain Research 142 (2005) 97–10698cells and sensory dorsal root ganglion cells [1,33,39,50]
leading to the phosphorylation and subsequent activation
of Akt/Protein Kinase B [2,18,21,44]. Active Akt in turn
can phosphorylate and thereby inactivate several cytoplas-
mic or nuclear targets such as the initiator caspase,
caspase-9 [9,33], the proapoptotic protein Bad and the
transcription factor FKHRL-1 [10,15,33]. A recent study in
non-neuronal cells has demonstrated that Akt can also
phosphorylate and activate the transcription factor CREB,
implicated in the transcription of the antiapoptotic bcl-2
gene [49].
This report analyses the effects of the anti-apoptotic
action of IGF-I on neuronal apoptosis using ceramide as
an apoptotic inducer. Ceramide is a second messenger
generated intracellularly by the sphingomyelinase-medi-
ated cleavage of sphingomyelin [23,29,38]. Sphingomye-
linase activity is strongly increased during develop-
mental neuronal death in rat brain [54]. Increased
ceramide levels are observed during apoptosis induced
by growth factor-withdrawal in neuronally differentiated
PC12 cells [32] or cortical neurons [62] and after
ischemia in the gerbil hippocampus [41]. Furthermore,
apoptosis can be induced by exogenous ceramide
treatment of PC12 cells [20,24], mesencephalic [7],
hippocampal [40] or cortical neurons [60]. Recently, we
have shown that ceramide regulates pro-apoptotic MAP
kinase pathways and that JNK and p38 activation is
crucial in ceramide-induced neuronal apoptosis in primary
cortical neurons [60,61]. Thus, the objective of this study
is to evaluate the protective effects of IGF-I on ceramide-
induced neuronal cell death in primary cortical neuronal
cultures.2. Materials and methods
2.1. Materials
2.1.1. Drugs
C2-ceramide (N-acetylsphingosine, Biomol Research
Lab, Plymouth Meeting, PA, USA) was prepared as a 25-
mM stock in ethanol and incubated in the culture media.
The specificity of c2-ceramide was evaluated by comparing
its effects with those of c2-dihydro-ceramide (Biomol
Research Lab). This analogue is lacking the 4–5 trans
double bond in the sphingosine moiety of c2-ceramide, and
is unable to activate the sphingomyelin pathway in
lymphocytes [4,45] and neurons [7].
Insulin-like growth factor-I (Sigma, Saint Louis, MO,
USA) was prepared as 0.1 M acid acetic stocks at 0,05 mg/
mL and added to the culture media as described. LY294002
(Cell Signaling Technology, Ozyme, France) was prepared
as DMSO stocks at 50 mM and added to the culture media
as described. ERK pathway inhibitor U0126 (Promega) was
prepared as DMSO stocks at 10 mM and added to the
culture media as described.2.1.2. Antibodies
We used Cell Signaling Technology rabbit antisera
specifically directed towards phospho-Ser473 Akt diluted
1:1000, phospho-Ser133 CREB diluted 1:750 for Western
blot or 1:500 for immunocytochemistry. We also used rabbit
polyclonal antisera raised against synthetic peptides specific
for Akt (phosphorylation-state independent; Cell Signaling
Technology) diluted 1:1000, mouse monoclonal antisera
raised against a recombinant Bcl-2 (Santa Cruz, Santa Cruz,
CA, USA) diluted 1:1000. Phospho-ERK (P-ERK) diluted
1:1000, ERK diluted 1:750 and CREB diluted 1:1000
antibodies were all rabbit antisera purchased from Cell
Signaling Technology.
2.1.3. Mice
The Swiss mice were purchased from Janvier (Le
Genest-St-Isle, France). Bcl-2 transgenic mice were gener-
ated from our breading colony, from mice kindly given by
Dr. Martinou, University of Geneva, Switzerland. Expres-
sion of Bcl-2 in these transgenic mice has been previously
published [17,37]. Adequate measures were taken to
minimize the number of animals used, pain or discomfort.
All experiments conformed to French guidelines on the
ethical use of animals and European Communities Council
Directive of 24 November 1986 (86/609/EEC).
2.2. Genotyping
Genotyping for bcl-2 was performed by PCR using two
primers to detect the human bcl-2 transgene: forward 5V-
ATGAGCCTTGGGACTGTGAA-3V, reverse 5V-GAA-
GACTCTGCTCAGTTTGG-3V. Cycling parameters were 5
min at 94 -C for one cycle, 45 s at 94 -C, 45 s at 60 -C, 1
min at 72 -C for a total of 40 cycles. PCR products were
resolved on a 2% agarose gel.
2.3. Primary cultures of mouse cortex
Embryos were removed at day 14 from timed-pregnant
Swiss mice (Janvier, Le Genest-St-Isle, France). The cortex
was dissected, mechanically dissociated and plated on
polyethyleneimine (1 mg/mL) coated culture wells, in
Eagle’s basal medium (Eurobio, Les Ulis, France), supple-
mented with 5% horse serum (HS; Eurobio) and 2.5% fetal
calf serum (FCS; Eurobio), at a density of 7105 cells/cm2.
After 2 days in culture the media was replaced with N5
medium [26] with 180 mg/L glucose and changed daily;
FCS content was reduced to 1%; Ara-C (cytosine arabino-
side, 3 AM, Sigma, Saint Louis, MO, USA) was added to
prevent astrocyte proliferation (our cultures were at least
95% neuronal after this treatment), and MK-801 (1 AM,
Research Biochemicals International, Natick, MA, USA) to
prevent excitotoxicity [7,28].
Primary neuronal cultures taken from the bcl-2 trans-
genic mice were prepared using the cortex. The cortex from
one embryo provides approximately 4106 cells that we
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Each culture was derived from an individual embryo, as
genotyping was performed after putting the cells into
culture.
2.4. Ceramide treatment
Embryonic cortical neurons cultivated in 5% HS and
1% FCS, optimal conditions for their maturation and
differentiation were insensitive to c2-ceramide treatment.
That is why we reduced serum content to 1% HS, 24
h before any ceramide treatment [7]. Thus, the effects seen
were not due to partial serum deprivation but rather to
specific treatment, since control cells were in the same
serum conditions during the same time as the treated cells.
The culture conditions (concentration and time course)
under which c2-ceramide provokes cell death were
determined by a cell-viability test.
2.5. Cell viability
Cell viability was determined by counting viable cells
after a ten-min treatment with bisbenzimide (0.8 Ag/mL),
Triton X-100 (0.005%) or with the MTT assay (the
conversion of the yellow tetrazolium salt [3(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT] to the
purple formazan dye depends upon the mitochondrial
activity [3,53]). The MTT assay was performed on neurons
in N5 medium 1% HS, with MTT (0.5 mg/mL) for 4 h in a
humidified atmosphere at 37 -C, 5% CO2. The purple
formazan salt was solubilized in 100 AL of a solution
containing 0.1 M HCl in isopropanol. The spectrophoto-
metric absorbency of the samples was determined at a 560-
nm wave length.
2.6. Transfections
Transient transfection of primary cortical cultures was
performed with LipofectAMINE 2000 (Invitrogen, Gronin-
gen, The Netherlands) as recommended by the manufactur-
er’s protocol. Cells were transfected with 1 Ag of a plasmid
encoding enhanced green fluorescent protein (pEGFP-N3;
Clontech, Cambridge, UK). After 6 h, the cultures were
rinsed with fresh media. Transfection efficacy was 3–5% of
the cells. After treatments, the cells were fixed as described
for immunocytochemistry.
2.7. Western blot analysis
Cultured neurons were lysed in solubilization buffer (10
mM Tris–HCl, 50 mM NaCl, 1% Triton X-100, 30 mM
Na4P2O7, 50 mM NaF, 5 AM ZnCl2, 100 AM Na3VO4, 1
mM dithiothreitol, 5 nM okadaic acid, 2.5 Ag/mL aprotinin,
3.6 AM pepstatin, 0.5 AM phenylmethylsulfonyl fluoride,
0.5 mM benzamidine, 5.3 AM leupeptin) at 4 -C. Insoluble
materials were removed by centrifugation (13,000 g for 20min at 4 -C), supernatants were isolated and the samples
were stored at 80 -C. Proteins were dosed with the DC
protein assay kit (Bio-Rad, Hercules, CA, USA). Cell-
extracts containing equivalent amounts of protein were
boiled for 5 min in sample loading buffer. After a 10% (15%
for Bcl-2 detection) SDS-PAGE, proteins were transferred
to a polyvinylidene difluoride membrane (ICN Bioche-
micals, Costa Mesa, CA USA). The transfer was checked by
Coomassie blue staining of the gels and the equal gel
loading was confirmed by Ponceau red staining of the
membranes. The transfer was also checked by the
homogenous background of the blots after revelation.
Non-specific sites were blocked with 5% skimmed dried
milk for 2 h. Blots were then incubated overnight at 4 -C
with primary antibodies against the phosphorylated form of
the kinases, in 5% Bovine Serum Albumin (BSA). They
were then incubated with horseradish peroxidase-conju-
gated secondary antibodies in 5% skimmed dried milk for
1 h. The revelation was processed with enhanced
chemiluminescence substrate (Amersham, UK). The blots
were stripped with 0.1 M glycine–HCl (pH 2.8) twice
for 30 min at 60 -C and SDS 2% for 10 min, followed
by saturation in 5% skimmed dried milk overnight at 4 -C.
They were then incubated with the primary antibodies
detecting both phosphorylated and non-phosphorylated
forms of the kinases, in 5% skimmed dried milk, followed
by incubation with the secondary antibody for 1 h, and
revealed with the ECL kit as described above. Quantification
was processed using the Densylab software (Microvision
Instruments).
2.8. Immunocytochemistry
After c2-ceramide treatment, cells were fixed with PBS
(Phosphate Buffer Saline) containing 2% paraformalde-
hyde for 40 min, and then incubated with methanol/
acetone solution (50/50) for 10 min at 4 -C. After washing
three times with PBS, plates were treated with blocking
buffer containing FCS 10%, BSA 3% Triton X-100 0.2%
in PBS for 30 min. Polyclonal antibody raised against
phosphorylated CREB was incubated overnight at 4 -C in
PBS containing 1% BSA and 0.2% Triton X-100. Plates
were rinsed 3 times in PBS and then incubated with an
anti-rabbit Cy3-conjugated antibody (1:2000) for 1.5 h in
PBS containing BSA 1%, Triton X-100 0.2%. After
counterstaining with Hoechst, cells were mounted under
coverslips using Vectashield (Vector Abcys, France).3. Results
3.1. IGF-I protects cortical neurons against
ceramide-induced apoptosis
The effect of IGF-I on ceramide-induced apoptosis was
examined in primary cortical neurons. Cortical neurons
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ceramide (40 AM) and IGF-I (10 ng/mL), then assayed for
cell viability at various times after treatment using the MTT
metabolism assay (Fig. 1A). By measuring survival, we
have shown that IGF-I inhibited ceramide-induced apopto-
sis. From 16 h until 48 h of treatment, co-treatment of
ceramide with IGF-I resulted in a survival increase from
61% to 97% at 24 h, and from 50% to 84% at 48 h (Fig.
1A). Furthermore, dose dependence analysis (Fig. 1B)
reveals that a dose of 5 ng/mL completely protects cortical
neurons from ceramide-induced apoptosis.
GFP transfection of the neurons allowed determination
of their morphology during treatment. After 24 h of
ceramide treatment, apoptotic features such as neurite
fragmentation and nuclear condensation and fragmentation
were observed (Figs. 1D and H). In IGF-I treated cells,
GFP labeling visualized intact neurons with long neurites,
as observed in the untreated control cells (Figs. 1C and E).
When cells were co-treated with ceramide and IGF-I, cells
looked healthy similar to control cells (Fig. 1F). In
conclusion, we show that IGF-I protects neurons against
ceramide-induced apoptosis, and that such protected
neurons show no signs of nuclear fragmentation and
condensation or neurite fragmentation.Fig. 1. IGF-I (10 ng/mL) protects cultured cortical neurons against c2-ceramid
dependent. Survival was assessed using the MTT assay. Data represent mean T S
(B). *P < 0.05 compared with the control value, according to the one-way ANOV
ceramide value, according to the Student’s t test. (C–J) GFP visualization of t
Hoechst (G–J), in control (C, G), c2-ceramide treated (40 AM; D, F, H, J), and/or
arrows: nuclei corresponding to GFP transfected cells. Scale bar: 20 AM.3.2. Ceramide decreases P-Akt, whereas IGF-I increases it,
even in presence of ceramide
In non-neuronal cells, ceramide has been shown to
inhibit the PI-3K/Akt pathway. To determine whether this
pathway is modulated during ceramide-induced neuronal
apoptosis, Western blots of cellular extracts were performed
with antibodies directed against the phosphorylated form of
Akt. As ceramide inhibits Akt by promoting dephosphor-
ylation of serine 473 [52] and phosphorylation of both
residues is required for the optimal activation of Akt [31],
we analyzed phosphorylation of serine 473. After 0.5 h, c2-
ceramide treatment resulted in a rapid and substantial
decrease in the signals corresponding to P-Ser473-Akt (Fig.
2A, first panel) without significantly affecting the level of
total Akt (Fig. 2A, second panel). The ratio P-Akt/total Akt
decreased very rapidly during c2-ceramide treatment and
reached 15% of the control value after a 0.5-h treatment, this
low phosphorylation level remained throughout the apopto-
tic process (up to a 24-h treatment; Fig. 2B).
In contrast, a 0.5-h co-treatment of c2-ceramide and IGF-
I caused a rapid and substantial increase in signals
corresponding to P-Ser473-Akt (Fig. 2A, third panel) without
significantly affecting the level of total Akt (Fig. 2A, fourthe (40 AM)-induced neuronal death. The effect is time-(A) and-dose (B)
EM, n = 6 independent experiments (A), n = 4 independent experiments
A followed by Dunnett’s post hoc test. **P < 0.05 compared with related
ransfected cortical neurons (C–F) and corresponding nuclei labeled with
IGF-I treated (10 ng/mL; E, F, I, J) neurons after 24 h of treatment. White
Fig. 2. IGF-I protection of cortical neurons implicates PI-3K/Akt pathway.
(A) Immunoblot analysis of P-Akt (first and third panels) and total Akt
(second and fourth panels) in extracts of c2-ceramide (40 AM; first and
second panels) or c2-ceramide (40 AM) and IGF-I (10 ng/mL; third and
fourth panels)-treated cortical neurons. (B) Quantification of P-Akt
immunoreactivity during c2-ceramide (40 AM) or c2-ceramide (40 AM)
and IGF-I (10 ng/mL) treatment. P-Akt signals were normalized to the
corresponding total Akt signals. Data represent mean T SEM, n = 3
independent experiments. *P < 0.05 compared with the control value,
according to the one-way ANOVA followed by Dunnett’s post hoc test. (C)
The PI-3K inhibitor LY294002 decreases survival. Survival measures were
obtained after 24 h of LY294002 (50 AM), IGF-I (10 ng/mL) and/or c2-
ceramide (40 AM) treatment. Survival was assessed using the MTT assay.
Data represent mean T SEM, n = 4 independent experiments. *P < 0.05
compared with the c2-ceramide value, according to the one-way ANOVA
followed by Dunnett’s post hoc test. (D) Immunoblot analysis of P-Akt in
extracts of 7-h treated cortical neurons with LY294002 (50 AM), IGF-I (10
ng/mL) and/or c2-ceramide (40 AM) treatment as indicated.
S. Willaime-Morawek et al. / Molecular Brain Research 142 (2005) 97–106 101panel). The ratio P-Akt/total Akt increased very rapidly
during c2-ceramide and IGF-I co-treatment and reached
304% of the control values after a 0.5-h treatment. Thisincrease in phosphorylation level was maintained through-
out the treatment (up to 24 h; Fig. 2B). Inhibition of PI-3K
by LY294002 abolishes IGF-I protection of cortical neurons
against ceramide-induced apoptosis.
To determine whether the PI-3K/Akt pathway is involved
in IGF-I protection against c2-ceramide-induced neuronal
cell death, we applied the PI-3K inhibitor LY294002. This
inhibitor is specific for PI-3K [13]. In Fig. 2C, ceramide
decreased survival to 57% of the control and IGF-I
protected neurons against ceramide-induced neuronal apo-
ptosis, as detailed in Fig. 1. LY294002 (50 AM) alone
decreased survival to 40% of the control. LY294002 did not
enhance ceramide-induced apoptosis after 24 h of treatment,
but abolished IGF-I protection of cortical neurons against
ceramide-induced neuronal apoptosis. Western blots of
cellular extracts with the same treatments were performed
with antibodies directed against the Ser473 phosphorylated
form of Akt (Fig. 2D). We observe that when survival level
was similar to the control value (control, IGF-I, cer+IGF-I),
Akt was phosphorylated, whereas when apoptosis was
induced (cer, LY, IGF-I+LY, cer+LY, cer+IGF-I+LY), the
level of Akt phosphorylation was low or indetectable.
3.3. Ceramide causes a decrease in CREB phosphorylation
in cortical neurons
As Akt may phosphorylate and activate CREB, we tested
whether the phosphorylated form of CREB (P-CREB) was
modulated during ceramide and/or IGF-I treatment. Western
blot analyses of cellular extracts were performed after 7 h of
treatment with ceramide and/or IGF-I (Fig. 3A), the time
corresponding to the highest level of Akt phosphorylation
during IGF-I and ceramide treatment, and also the minimum
level of Akt phosphorylation during ceramide treatment
alone (Fig. 2B). Ceramide treatment decreased CREB
phosphorylation compared to control values, whereas IGF-
I treatment increased CREB phosphorylation. Thus IGF-I is
able to induce CREB activity. However, when ceramide and
IGF-I were applied in tandem, CREB phosphorylation
decreased to the same level as the one after ceramide
treatment alone. We also performed a more detailed kinetic
analysis of P-CREB during ceramide and ceramide+IGF-I
treatments, but there was no difference in the level of CREB
phosphorylation at any time between both treatments (data
not shown). Furthermore, we performed a P-CREB analysis
after 1 h of the same different treatments as presented in Fig.
3A, and we got the exact same results as the one shown in
Fig. 3A (data not shown).
Immunocytochemical detection of P-CREB confirmed
these results (Figs. 3B–I). A basal level of P-CREB
immunoreactivity was found in the nuclei of control cells
(Figs. 3B and J), whereas after 7 h of c2-ceramide (40 AM)
treatment, P-CREB immunoreactivity was distinctly de-
creased (Figs. 3C and J). After IGF-I treatment, P-CREB
immunoreactivity was increased (Figs. 3D and J), whereas
ceramide+IGF-I treatment (Figs. 3E and J) decreased
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Fig. 4. (A) Survival after 24 h of c2-ceramide (40 AM) treatment of cortical
neurons from mice overexpressing Bcl-2 and wild-type littermate. Survival
was assessed counting viable cells with intact nuclei after Hoechst labeling.
Data represent mean T SEM, n = 13 independent experiments, *P < 0.05
compared with wild-type (+/+) value, according to the Student’s t test. (B)
Immunoblot analysis of Bcl-2 in extracts of 7-h treated cortical neurons as
indicated. Quantification of Bcl-2 immunoreactivity during c2-ceramide (40
AM), IGF-I (10 ng/mL) and/or LY294002 (50 AM) treatment. Data
represent mean T SEM, n = 5 independent experiments. P > 0.05 compared
with the control value, according to the one-way ANOVA followed by
Dunnett’s post hoc test.
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Thus, CREB phosphorylation is not involved in the IGF-I
protection against ceramide-induced neuronal apoptosis.
3.4. The PI-3K/Akt pathway is involved in IGF-I-induced
phosphorylation of CREB
To test if the PI-3K/Akt pathway is involved in CREB
phosphorylation, we performed Western blot analyses of
cellular extracts treated with ceramide, IGF-I and/or
LY294002 during 7 h (Fig. 3A). These experiments revealed
that LY294002 treatment alone, or in tandem with ceramide,
had no effect on CREB phosphorylation. We also showed
that LY294002 inhibited IGF-I induced-phosphorylation of
CREB (compare IGF to IGF+LY treatments in Fig. 3A), but
did not further decrease CREB phosphorylation after
cer+IGF+LY treatment, compared to cer+IGF-I treatment.
In conclusion, PI-3K is involved in IGF-induced phosphor-
ylation of CREB but PI-3K inhibition is not involved in the
basal phosphorylation of CREB, nor in CREB phosphory-
lation decrease induced by ceramide.
3.5. The ERK pathway is involved in IGF-I-induced
phosphorylation of CREB and in IGF-I-mediated protection
of cortical neurons
To investigate how ceramide antagonizes the stimulatory
actions of IGF-I on CREB, we performed Western blot
analyses of cellular extracts treated with IGF-I, c2-ceramide
and/or the ERK pathway inhibitor, U0126, during 7 h. We
showed that IGF-I increases CREB phosphorylation (Figs.
3A, J and K), and that U0126 treatment decreases CREB
phosphorylation, even in the presence of IGF-I (Fig. 3K).
We also showed that IGF-I-induced ERK phosphorylation is
abolished by U0126. In addition, we showed that ceramide
or U0126, with or without IGF-I, induces a decrease in P-
CREB phosphorylation (Figs. 3A and K). In conclusion, the
ERK pathway is involved in the basal and in IGF-I-induced
phosphorylation of CREB.
To see if the ERK pathway is also involved in the
survival of cortical neurons, we performed survival experi-
ments after treatment with IGF-I, c2-ceramide and/or the
ERK pathway inhibitor, U0126, during 24 h. As we have
already shown [60], inhibition of the ERK pathway does notFig. 3. (A) Immunoblot analysis of P-CREB in extracts of 7-h treated cortical ne
ceramide (40 AM), IGF-I (10 ng/mL) and/or LY294002 (50 AM) treatments. P-CRE
shown). Data represent mean T SEM, n = 8 independent experiments. *P < 0.05 co
by Dunnett’s post hoc test. (B–I) C2-ceramide induces a decrease of P-CREB in t
(red; B–E) and nuclear labeled by Hoechst (blue, F– I) in cortical cultures. Neuron
IGF-I (10 ng/mL; D, E, H, I) during 7 h. White arrows: examples of P-CREB positi
Figs. 4B–I immunocytochemistry experiments. Data represent mean T SEM, n =
according to the one-way ANOVA followed by Dunnett’s post hoc test. (K) Immun
7-h IGF-I (10 ng/mL), c2-ceramide (40 AM) and/or ERK pathway inhibitor U012
pathway. Survival measures were obtained after 24 h of U0126 (10 AM), IGF-I (1
counting viable cells after treatment with bisbenzimide. Data represent mean T S
ceramide value, according to the one-way ANOVA followed by Dunnett’s post haffect neuronal survival in control conditions, nor does it
affect ceramide-induced apoptosis (Fig. 3L). We showed
here that U0126 abolishes IGF-I-mediated protection
against ceramide-induced apoptosis (compare cer+IGF and
cer+IGF+U0126 in Fig. 3L). Thus, the ERK pathway is
involved in IGF-I-mediated protection of cortical neurons
against ceramide-induced apoptosis.
3.6. Bcl-2 is not involved in cortical neurons protection
against ceramide-induced apoptosis
As the transcription factor CREB may regulate bcl-2
gene, we examined the effect of Bcl-2 on ceramide-induced
apoptosis in primary cortical neurons from transgenic miceurons as indicated. Quantification of P-CREB immunoreactivity during c2-
B signals were normalized to the corresponding total CREB signal (data not
mpared with the control value, according to the one-way ANOVA followed
he nuclei of cultured cortical neurons. Neurons immunostained for P-CREB
s control (B, F), treated with c2-ceramide (40 AM; C, E, G, I) or treated with
ve cells. Scale bar: 20 AM. (J) Quantification of P-CREB positive cells from
3 independent experiments. *P < 0.05 compared with the control value,
oblot analysis of P-CREB, total CREB, P-ERK and total ERK in extracts of
6 (10 AM)-treated cortical neurons. (L) IGF-I protection involves the ERK
0 ng/mL) and/or c2-ceramide (40 AM) treatment. Survival was assessed by
EM, n = 15 from 3 independent wells. *P < 0.05 compared with the c2-
oc test.
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a 5-day maturation period in vitro, cultures were treated
with c2-ceramide (40 AM) and assayed for cell viability 24
h after treatment by counting cells with normal nuclei
labeled with bisbenzimide (Fig. 4A). Our results show that
bcl-2 overexpression inhibited ceramide-induced apoptosis
and protected cortical neurons: 91% bcl-2 overexpressing
neurons survived compared to 59% of the wild type. Thus,
Bcl-2 protects cortical neurons against ceramide-induced
apoptosis. The same cellular extracts as in Fig. 3A were
submitted to Bcl-2 detection by Western blot (Fig. 4B). We
showed that Bcl-2 protein level was not modulated by
ceramide, IGF-I, or LY294002. In all conditions tested, the
Bcl-2 protein level was comparable to the one of the control.
We also performed a more detailed kinetic analysis of Bcl-2
during ceramide and ceramide+IGF treatments. As a result,
we did not see any difference in the level of Bcl-2 protein at
longer time points between both treatments (data not
shown). Furthermore, we performed Bcl-2 analysis after 1
h of the same different treatments as presented in Fig. 4B,
and we got the exact same results as the one shown in Fig.
4B (data not shown). Thus, although overexpression of Bcl-
2 protects cortical neurons against ceramide-induced apo-
ptosis, there is no modulation of Bcl-2 protein level in IGF
protection against ceramide-induced apoptosis.4. Discussion
The objective of this study was to investigate the effects
of IGF-I on ceramide-induced neuronal apoptosis, and the
possible link between this molecule and the PI-3K/Akt/
CREB/Bcl-2 pathway in cortical neurons.
We showed for the first time that IGF-I protects cortical
neurons from ceramide-induced apoptosis. IGF-I protection
from ceramide has previously been shown in non-neuronal
cells [30,36]. IGF-I has been also shown to protect
hippocampal neurons from h-amyloid peptide toxicity
[16], dorsal root ganglion neurons from Nerve Growth
Factor withdrawal [59] and cortical neurons from hypoxia
[58].
Pugazhenthi and his coworkers have proposed a link
between IGF-I and the PI-3K/Akt/CREB/Bcl-2 pathway
[48,49]. To test this hypothesis in cortical neurons, we
analyzed Akt phosphorylation during ceramide treatment
with or without IGF-I and PI-3K inhibitor. Using these
different treatments, we have shown that when survival
level was similar to the control value, Akt was phosphor-
ylated, whereas when survival was low, Akt phosphoryla-
tion level was also low or undetectable. Thus, Akt seems to
be a key enzyme for cortical neurons survival. A minimal
activation of the PI-3K pathway is required for the survival
of neurons; indeed, the levels of neuronal survival are in
agreement with the immunoblotting raised against phospho-
Akt (taken as a test of PI-3K activity) in the control situation
and after treatment by LY alone: when PI-3K pathway isinhibited, the neuronal survival is decreased. The inhibition
of Akt by ceramide may be mediated by several processes.
Ceramide may decrease Akt phosphorylation by inhibiting
PI-3K or PDK2, kinases upstream of Akt. This might be the
case in our model, since (i) Akt has a low undetectable level
of phosphorylation during ceramide treatment with or
without LY294002; and (ii) IGF-I-induced phosphorylation
of Akt has been shown to involve PI-3K and PDK2
[14,25,43,46]. However the intermediates between ceramide
and PI-3K or PDK2 have not been identified yet. We cannot
exclude other mechanisms for ceramide-decreasing Akt
phosphorylation, such as dephosphorylation of Akt by a
Protein Phosphatase-2A-like phosphatase (PP2A), Ceramide
Activated Protein Phosphatase (CAPP) [51] or PKC~ [5].
Since IGF-I and Akt promote neuronal survival, we
examined a possible downstream effector, the transcription
factor CREB. In accordance with previous results on non-
neuronal cells [47,49], we have shown for the first time in
neurons, that IGF-I induced CREB phosphorylation via PI-
3K and ERK. However, our data demonstrate that CREB
and Akt phosphorylations are not coupled, and that the
neuronal survival is independent of CREB. Indeed, during
ceramide and IGF-I treatment, neurons are protected, Akt
phosphorylation increased but CREB phosphorylation
decreased. Moreover, our experiments revealed that ERK
is involved in the basal and in the IGF-I-induced phosphor-
ylation of CREB. We also showed that IGF-I-mediated
protection against ceramide-induced apoptosis involves the
ERK pathway but not CREB. Thus, CREB is not linked to
neuronal survival.
Our data showed that cortical neurons overexpressing
Bcl-2 were protected from ceramide-induced apoptosis. A
protective role of Bcl-2 from ceramide-induced apoptosis
has previously been observed in two neuronal cell lines
[19,63] probably by blocking the release of cytochrome c
from the mitochondria into the cytosol [27,62]. However,
immunoblotting experiments of Bcl-2 showed that Bcl-2
expression was not modulated during IGF-I, ceramide or
LY294002 treatments. In consequence, Bcl-2 is not
involved in IGF-I mediated protection. From this experi-
ment we can conclude, that Akt does not act via CREB or
Bcl-2 to protect neurons against ceramide-induced apopto-
sis. Akt may act on other proteins such as the transcription
factor Forkhead or cytoplasmic proteins Bad, caspase-9 or
InB Kinase (for review see [6,8,11]). Moreover, a recent
study shows that ceramide may act on Bad and Forkhead
during neuronal apoptosis [55].
To summarize our results, in control conditions, the PI-
3K/Akt pathway is involved in the survival of cortical
neurons and the ERK pathway is involved in CREB
phosphorylation. When neurons are treated with IGF-I, the
ERK and PI-3K/Akt pathways are involved in CREB
phosphorylation. When ceramide induces neuronal apopto-
sis, the ERK and PI-3K/Akt pathways, as well as CREB, are
inhibited. We demonstrate for the first time that IGF-I
protects neurons against ceramide-induced neuronal apopto-
S. Willaime-Morawek et al. / Molecular Brain Research 142 (2005) 97–106 105sis and that this protection involves the ERK and PI-3K/Akt
pathways, but may be independent of CREB and Bcl-2.Acknowledgments
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